|
1
|
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
|
N Engl J Med
|
2005
|
12.99
|
|
2
|
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|
J Clin Oncol
|
2005
|
8.87
|
|
3
|
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
|
J Clin Oncol
|
2007
|
7.45
|
|
4
|
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
|
J Clin Oncol
|
2002
|
4.47
|
|
5
|
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
|
N Engl J Med
|
2009
|
4.16
|
|
6
|
Retracted
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
|
Lancet Oncol
|
2007
|
3.67
|
|
7
|
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
|
J Clin Oncol
|
2011
|
3.53
|
|
8
|
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
|
J Clin Oncol
|
2008
|
2.66
|
|
9
|
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group.
|
Eur J Cancer
|
2010
|
2.62
|
|
10
|
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
|
Lancet Oncol
|
2011
|
2.51
|
|
11
|
Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomes.
|
Radiology
|
2012
|
2.10
|
|
12
|
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
|
Cancer Res
|
2003
|
2.04
|
|
13
|
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
|
Lancet Oncol
|
2011
|
1.85
|
|
14
|
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
|
Cancer
|
2003
|
1.72
|
|
15
|
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.
|
Clin Cancer Res
|
2008
|
1.66
|
|
16
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
|
J Clin Oncol
|
2007
|
1.60
|
|
17
|
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
|
Oncologist
|
2010
|
1.52
|
|
18
|
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.
|
Lancet Oncol
|
2005
|
1.48
|
|
19
|
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
|
J Clin Oncol
|
2008
|
1.34
|
|
20
|
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
|
J Clin Oncol
|
2004
|
1.16
|
|
21
|
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
|
Cancer
|
2005
|
1.04
|
|
22
|
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
|
J Clin Oncol
|
2007
|
1.04
|
|
23
|
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
|
Breast Cancer Res Treat
|
2010
|
1.00
|
|
24
|
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations.
|
Mod Pathol
|
2008
|
0.96
|
|
25
|
Epithelial atypia in biopsies performed for microcalcifications. practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-up.
|
Virchows Arch
|
2007
|
0.92
|
|
26
|
Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?
|
Cancer
|
2010
|
0.87
|
|
27
|
D2-40 in breast cancer: should we detect more vascular emboli?
|
Mod Pathol
|
2008
|
0.87
|
|
28
|
Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patients.
|
Ann Surg Oncol
|
2010
|
0.82
|
|
29
|
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.
|
Br J Cancer
|
2007
|
0.82
|
|
30
|
Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.
|
Clin Breast Cancer
|
2004
|
0.80
|
|
31
|
Time for reappraisal of progesterone-receptor testing in breast cancer management.
|
J Clin Oncol
|
2005
|
0.79
|
|
32
|
[Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004].
|
Bull Cancer
|
2005
|
0.79
|
|
33
|
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
|
Cancer Treat Rev
|
2005
|
0.78
|
|
34
|
First-line chemotherapy for metastatic breast cancer in patients ≥75 years: a retrospective single-centre analysis.
|
Crit Rev Oncol Hematol
|
2010
|
0.78
|
|
35
|
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
|
Lancet Oncol
|
2011
|
0.78
|
|
36
|
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
|
Oncology
|
2009
|
0.78
|
|
37
|
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
|
Cancer
|
2007
|
0.78
|
|
38
|
Distinction between isolated tumor cells and micrometastases in breast cancer: is it reliable and useful?
|
Cancer
|
2008
|
0.78
|
|
39
|
Re: Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.
|
J Natl Cancer Inst
|
2009
|
0.78
|
|
40
|
Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.
|
Anticancer Res
|
2007
|
0.77
|
|
41
|
[HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
|
Bull Cancer
|
2006
|
0.77
|
|
42
|
[Medical treatments of endocrine-sensitive Her-2 negative breast cancers: a review].
|
Bull Cancer
|
2011
|
0.77
|
|
43
|
Expression profiling in breast carcinoma: new insights on old prognostic factors?
|
J Clin Oncol
|
2007
|
0.75
|
|
44
|
Epithelial atypia: a marker risk of concomitant or subsequent breast carcinoma?
|
J Clin Oncol
|
2008
|
0.75
|
|
45
|
Spreading the word, but not too thinly.
|
Lancet
|
2004
|
0.75
|